The global Graves Ophthalmopathy Market, also known as Graves orbitopathy, exhibited significant strength in 2021 and is anticipated to achieve swift revenue growth compounded annually over the projected period. This growth trajectory in revenue for Graves ophthalmopathy treatment stems from the escalating prevalence of autoimmune disorders, boosted by factors such as dynamic research and development undertakings within ophthalmology, coupled with a mounting count of clinical trials aimed at addressing autoimmune ailments. However, the market's revenue ascent faces impediments due to the scarcity of FDA-approved medications for Graves ophthalmopathy treatment. https://www.reportsanddata.com/report-detail/graves-ophthalmopathy-market